A Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Compare the Efficacy and Safety of HG102 Versus Botox ® in Subjects With Moderate to Severe Glabellar Lines
Condition: Glabellar Lines Interventions: Drug: Botulinum Toxin Type A Injection [HG102]; Drug: Botulinum Toxin Type A Injection [Botox] Sponsor: Hugel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials